Brilliant Acquisition Corporation

Bio-Reference reported first-quarter fiscal 2015 net revenues of $208.833 million versus $181.270 million a year ago, up 15%. Gross profit was $89.755 million, or 43% of revenue, compared with $72.154 million and a 40% margin last year. Operating income was $11.928 million versus $5.880 million, EPS was $0.24 versus $0.11, patient count rose 7% to 2.352 million, and net revenue per patient increased 8% to $88.09 from $81.17. Working capital was $213.792 million, and DSO was 113 days versus 111 days last year. Management reaffirmed full-year guidance for greater than 10% growth in net revenues and 20% growth in net earnings.

Dr. Grodman framed the quarter as an “excellent” one and said it was the first in several years that was truly comparable year over year because of industry reimbursement changes and the company’s own investments. He emphasized that Bio-Reference is increasingly focused on precision diagnostics, genetics, and sequencing, and said the company is evolving with healthcare by becoming more provider-centric and expanding partnerships. His tone was confident and strategic, while also cautioning that reimbursement, regulation, and payer behavior remain important issues.

Sam Singer highlighted the hard numbers: revenue of $208.833 million, gross profit margin of 43%, operating income of $11.928 million, EPS of $0.24, patient count of 2.352 million, and revenue per patient of $88.09. He pointed to working capital of $213.792 million and DSO of 113 days, noting the DSO increase was mostly structural and tied to first-quarter seasonality rather than a meaningful deterioration in collections. Management also said first-quarter cash flow from operations was just over $10 million and free cash flow was just shy of $4.3 million, which they described as the strongest first-quarter free cash flow ever.

Analyst Amanda Murphy asked whether routine testing growth could improve through the year, whether sequential revenue softness was just normal first-quarter seasonality, whether price per accession could pick up, what drove the strong cash flow despite slightly higher DSOs, and how management viewed new next-gen coding efforts. Management said routine and regional testing can vary by segment and season, that the sequential decline is typical after the holiday-heavy fourth quarter, and that deductible timing can affect early-year elective testing. On cash flow, Grodman said the DSO move was mainly tied to sales seasonality rather than collections problems, and on coding he said there is still too much uncertainty to draw conclusions.